全文获取类型
收费全文 | 990128篇 |
免费 | 76697篇 |
国内免费 | 2604篇 |
专业分类
耳鼻咽喉 | 12947篇 |
儿科学 | 34374篇 |
妇产科学 | 28458篇 |
基础医学 | 144288篇 |
口腔科学 | 27672篇 |
临床医学 | 89721篇 |
内科学 | 191831篇 |
皮肤病学 | 22894篇 |
神经病学 | 78521篇 |
特种医学 | 38350篇 |
外国民族医学 | 305篇 |
外科学 | 149045篇 |
综合类 | 23688篇 |
一般理论 | 385篇 |
预防医学 | 77211篇 |
眼科学 | 22538篇 |
药学 | 71661篇 |
3篇 | |
中国医学 | 1955篇 |
肿瘤学 | 53582篇 |
出版年
2018年 | 10554篇 |
2017年 | 8233篇 |
2016年 | 9373篇 |
2015年 | 10594篇 |
2014年 | 14415篇 |
2013年 | 22000篇 |
2012年 | 28981篇 |
2011年 | 30824篇 |
2010年 | 18487篇 |
2009年 | 17436篇 |
2008年 | 28790篇 |
2007年 | 30459篇 |
2006年 | 30961篇 |
2005年 | 29641篇 |
2004年 | 28925篇 |
2003年 | 27730篇 |
2002年 | 26741篇 |
2001年 | 46842篇 |
2000年 | 47897篇 |
1999年 | 40003篇 |
1998年 | 10582篇 |
1997年 | 9521篇 |
1996年 | 9531篇 |
1995年 | 9719篇 |
1994年 | 9057篇 |
1993年 | 8426篇 |
1992年 | 32197篇 |
1991年 | 31445篇 |
1990年 | 30997篇 |
1989年 | 29856篇 |
1988年 | 27144篇 |
1987年 | 27315篇 |
1986年 | 25403篇 |
1985年 | 24584篇 |
1984年 | 18364篇 |
1983年 | 15461篇 |
1982年 | 9249篇 |
1981年 | 8331篇 |
1979年 | 16822篇 |
1978年 | 12191篇 |
1977年 | 10281篇 |
1976年 | 9718篇 |
1975年 | 10153篇 |
1974年 | 12298篇 |
1973年 | 11827篇 |
1972年 | 10878篇 |
1971年 | 10104篇 |
1970年 | 9370篇 |
1969年 | 8713篇 |
1968年 | 8093篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Usha Patel Manish Pandey Sadhana Kannan Tanuja A. Samant Poonam Gera Neha Mittal Swapnil Rane Asawari Patil Vanita Noronha Amit Joshi Vijay M. Patil Kumar Prabhash Manoj B. Mahimkar 《British journal of cancer》2020,123(12):1757
Background Anti-EGFR-based therapies have limited success in HNSCC patients. Predictive biomarkers are greatly needed to identify the patients likely to be benefited from these targeted therapies. Here, we present the prognostic and predictive association of biomarkers in HPV-negative locally advanced (LA) HNSCC patients.Methods Treatment-naive tumour tissue samples of 404 patients, a subset of randomised Phase 3 trial comparing cisplatin radiation (CRT) versus nimotuzumab plus cisplatin radiation (NCRT) were analysed to evaluate the expression of HIF1α, EGFR and pEGFR by immunohistochemistry and EGFR gene copy change by FISH. Progression-free survival (PFS), locoregional control (LRC) and overall survival (OS) were estimated by Kaplan–Meier method. Hazard ratios were estimated by Cox proportional hazard models.Results Baseline characteristics of the patients were balanced between two treatment groups (CRT vs NCRT) and were representative of the trial cohort. The median follow-up was of 39.13 months. Low HIF1α was associated with better PFS [HR (95% CI) = 0.62 (0.42–0.93)], LRC [HR (95% CI) = 0.56 (0.37–0.86)] and OS [HR (95% CI) = 0.63 (0.43–0.93)] in the CRT group. Multivariable analysis revealed HIF1α as an independent negative prognostic biomarker. For patients with high HIF1α, NCRT significantly improved the outcomes [PFS:HR (95% CI) = 0.55 (0.37–0.82), LRC:HR (95% CI) = 0.55 (0.36–0.85) and OS:HR (95% CI) = 0.54 (0.36–0.81)] compared to CRT. While in patients with low HIF1α, no difference in the clinical outcomes was observed between treatments. Interaction test suggested a predictive value of HIF1α for OS (P = 0.008).Conclusions High HIF1α expression is a predictor of poor clinical response to CRT in HPV-negative LA-HNSCC patients. These patients with high HIF1α significantly benefited with the addition of nimotuzumab to CRT.Clinical trial registration Registered with the Clinical Trial Registry of India (Trial registration identifier—CTRI/2014/09/004980).Subject terms: Tumour biomarkers, Head and neck cancer, Tumour biomarkers, Head and neck cancer, Predictive markers 相似文献
992.
Katrina Hueniken MPH Catriona M. Douglas BSc MBChB MD Ashok R. Jethwa MD Maryam Mirshams MSc Lawson Eng MD Andrew Hope MD Douglas B. Chepeha MD David P. Goldstein MD MSc Jolie Ringash MD MSc Aaron Hansen BSc MBBS Rosemary Martino PhD Madeline Li MD PhD Geoffrey Liu MD Wei Xu MD John R. de Almeida MD MSc 《Cancer》2020,126(17):4042-4050
993.
Jared M. Weiss MD Nathan Pennell MD PhD Allison M. Deal MS Daniel Morgensztern MD Daniel S. Bradford MD Jeffrey Crane MD Howard Jack West MD Carrie Lee MD Chad Pecot MD James P. Stevenson MD William Irvin MD Mark Socinski MD Tom Stinchcombe MD Liza C. Villaruz MD Hyman B. Muss MD 《Cancer》2020,126(5):1060-1067
994.
Sebastian Zschaeck Yimin Li Rebecca Bütof Chen Lili Wu Hua Esther C.G. Troost Marcus Beck Holger Amthauer David Kaul Jörg Kotzerke Alexander D.J. Baur Pirus Ghadjar Michael Baumann Mechthild Krause Frank Hofheinz 《International journal of cancer. Journal international du cancer》2020,147(5):1427-1436
We have investigated the prognostic value of two novel interim 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) parameters in patients undergoing chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): one tumor parameter (maximal standardized uptake ratio rSUR) and one normal tissue parameter (change of FDG uptake within irradiated nontumor-affected esophagus ∆SUVNTO). PET data of 134 European and Chinese patients were analyzed. Parameter establishment was based on 36 patients undergoing preoperative CRT plus surgery, validation was performed in 98 patients receiving definitive CRT. Patients received PET imaging prior and during fourth week of CRT. Clinical parameters, baseline PET parameters, and interim PET parameters (rSUR and ∆SUVNTO) were analyzed and compared to event-free survival (EFS), overall survival (OS), loco-regional control (LRC) and freedom from distant metastases (FFDM). Combining rSUR and ∆SUVNTO revealed a strong prognostic impact on EFS, OS, LRC and FFDM in patients undergoing preoperative CRT. In the definitive CRT cohort, univariate analysis with respect to EFS revealed several staging plus both previously established interim PET parameters as significant prognostic factors. Multivariate analyses revealed only rSUR and ∆SUVNTO as independent prognostic factors (p = 0.003, p = 0.008). Combination of these parameters with the cutoff established in preoperative CRT revealed excellent discrimination of patients with a long or short EFS (73% vs. 17% at 2 years, respectively) and significantly discriminated all other endpoints (OS, p < 0.001; LRC, p < 0.001; FFDM, p = 0.02), even in subgroups. Combined use of interim FDG-PET derived parameters ∆SUVNTO and rSUR seems to have predictive potential, allowing to select responders for definitive CRT and omission of surgery. 相似文献
995.
996.
Kelly A. Reynolds Deeti J Pithadia Erica B Lee George Han 《Expert opinion on drug safety》2020,19(4):459-466
ABSTRACTIntroduction: Many tumor necrosis factor (TNF)-alpha ‘biosimilar’ agents have been approved for the treatment of psoriasis and other autoinflammatory conditions. These biosimilars have the same structure as the originator biologic and have been shown to be equivalent in terms of safety and efficacy. However, given the method by which biosimilars are manufactured, they are not exact replicas of the originator, unlike generic forms of non-biologic medications. Therefore, there is controversy regarding whether these agents should be considered interchangeable with their originator biologics.Areas covered: The objective of this review is to summarize the safety data for each of the approved TNF-alpha biosimilars to determine whether or not these agents have appropriate safety profiles to replace their originator biologics.Expert opinion: Based on extrapolation of phase III investigations in patients with rheumatologic diseases, each of the approved anti-TNF agents have comparable efficacy, tolerability, and safety profiles to their originators. Studies in patients with psoriasis are more limited. Transitioning from a biologic to its biosimilar has also been shown to be similarly safe and immunogenetic compared to maintenance therapy with the originator. More post-marketing studies are needed to demonstrate the long-term safety in patients with psoriasis. 相似文献
997.
998.
Philippe A. Eigenmann Motohiro Ebisawa Matthew Greenhawt Jonathan O’B Hourihane Tamara T. Perry Benjamin C. Remington Robert A. Wood 《Pediatric allergy and immunology》2021,32(4):658-666
Risk is a concept inherent in every medical procedure. It can be defined as the probability of an adverse event in a defined population over a specified period of time. In the frame of food allergy management, it might be related to a diagnostic procedure, a treatment, or the consumption of foods. The risk of an adverse event can also be augmented by individual factors. This rostrum article discusses various aspects faced by children with food allergies in the light of risk, and their practical implications. Identifying personal risks for severe reaction, such as unstable asthma, and correcting them whenever possible also contribute to a reduction of the risk inherent to food allergy. Among the facets discussed, oral food challenges (OFC) are the most common diagnostic procedures implying an inherent risk. The risk of OFCs can be minimized by correct indication and timing of the test, a safe setting, as well as by ensuring that the patient is otherwise well without potential stressor potentially increasing the risk of a more severe reaction. Oral immunotherapy (OIT) has been studied as a potential treatment for increasing the threshold dose for reaction, and thus reducing the risk of accidental reaction. Nevertheless, the procedure is not devoid of risk as the patients may and do often react during the course of the procedure. Ingestion of trace amounts in processed foods, mainly in community settings such as restaurants, schools, or day care, represents a potential risk of reactions, although for a minority of patients. Precautionary allergen labeling (PAL) is a widespread strategy to reduce the potential risk of reactions due to traces. However, PAL is currently inefficient due to inconsistent labeling, also not indicating a clear maximum amount possibly present in the manufactured food. Finally, cost-effectiveness needs to be considered in risk management, as many risk reduction procedures are clearly not cost-effective. 相似文献
999.
Marta Revilla-Leon Kevin Frazier Juliana B. da Costa Purnima Kumar Mai-Ly Duong Sharukh Khajotia Olivia Urquhart 《Journal of the American Dental Association (1939)》2021,152(8):669-670.e2
BackgroundDentists may choose to integrate intraoral scanners (IOSs) into their practices, but there are many different IOS technologies and system generations to choose from, posing a challenge for dentists who want to invest in them.MethodsA survey of IOS use rates, advantages, satisfaction, and training was developed and deployed through Qualtrics to the 968 members of the American Dental Association Clinical Evaluators (ACE) Panel on February 19, 2021. Nonrespondents were sent reminders, and data were analyzed in SAS Version 9.4 (SAS).ResultsA total of 369 panelists responded to the survey. IOS use was split among the ACE Panel; 53% indicated they use one in their practice. The top reason respondents began using IOSs was to improve clinical efficiency (70%). Ninety percent of respondents use IOSs for single tooth-supported crowns, and 58% began using IOSs less than 4 years ago. Most users are at least mostly satisfied (91%) with the results. Among nonusers, the top reason for not using an IOS was the high level of financial investment (66%); 34% and 40% of nonusers are thinking of buying or training with IOSs in 2021, respectively.ConclusionsUptake of IOSs is split; most users are satisfied with their results, and nonusers cited financial barriers as the most common reason for not investing in one.Practical ImplicationsAs IOSs continue to penetrate the market and dentists are faced with a decision whether to invest in one, they will need guidance on how to choose the most appropriate device for their patients. 相似文献
1000.